Symptoms
Common signs and symptoms of Spinal Muscular Atrophy include:
When to see a doctor
If you experience severe or worsening symptoms, seek immediate medical attention. Always consult with a healthcare professional for proper diagnosis and treatment.
Causes & Risk Factors
Several factors can contribute to Spinal Muscular Atrophy.
Spinal muscular atrophy stems from mutations in the SMN1 gene, which provides instructions for making a protein called survival motor neuron protein.
Spinal muscular atrophy stems from mutations in the SMN1 gene, which provides instructions for making a protein called survival motor neuron protein. Think of this protein as essential fuel for motor neurons - the nerve cells that control muscle movement. Without enough of this protein, motor neurons in the spinal cord gradually die off.
Most people have a backup gene called SMN2 that can produce some survival motor neuron protein, but not nearly enough to fully compensate.
Most people have a backup gene called SMN2 that can produce some survival motor neuron protein, but not nearly enough to fully compensate. The number of SMN2 gene copies a person has often determines how severe their condition becomes. More copies generally mean milder symptoms, while fewer copies typically lead to more severe forms of the disease.
This genetic condition follows an autosomal recessive pattern, meaning both parents must carry the faulty gene for their child to develop spinal muscular atrophy.
This genetic condition follows an autosomal recessive pattern, meaning both parents must carry the faulty gene for their child to develop spinal muscular atrophy. Parents who carry one copy of the mutation typically show no symptoms themselves but have a 25% chance with each pregnancy of having an affected child.
Risk Factors
- Both parents carrying SMN1 gene mutations
- Family history of spinal muscular atrophy
- Being a carrier of SMN1 gene deletions
- Certain ethnic backgrounds with higher carrier rates
- Consanguineous marriages increasing genetic risk
- Previous child with spinal muscular atrophy
Diagnosis
How healthcare professionals diagnose Spinal Muscular Atrophy:
- 1
Doctors often first suspect spinal muscular atrophy when infants miss motor milestones or show progressive muscle weakness.
Doctors often first suspect spinal muscular atrophy when infants miss motor milestones or show progressive muscle weakness. The diagnostic process typically begins with a thorough physical examination and detailed family history. Pediatric neurologists look for characteristic signs like muscle weakness that affects the legs more than arms, absent or weak reflexes, and muscle wasting.
- 2
Genetic testing provides the definitive diagnosis.
Genetic testing provides the definitive diagnosis. A simple blood test can detect deletions in the SMN1 gene, which occur in about 95% of people with spinal muscular atrophy. Additional tests may include electromyography to measure electrical activity in muscles, muscle biopsies in rare cases, and genetic analysis to determine the number of SMN2 gene copies.
- 3
Early diagnosis has become increasingly important as new treatments work best when started as soon as possible.
Early diagnosis has become increasingly important as new treatments work best when started as soon as possible. Some countries now include spinal muscular atrophy in their newborn screening programs, allowing for identification and treatment before symptoms appear. Prenatal testing is also available for families with known genetic risk.
Complications
- Without treatment, spinal muscular atrophy can lead to serious complications that affect multiple body systems.
- Respiratory problems pose the greatest risk, as weakened breathing muscles can cause pneumonia, sleep apnea, and respiratory failure.
- Many people require assistance with airway clearance and may need mechanical ventilation support.
- Musculoskeletal complications develop as the condition progresses.
- Scoliosis occurs in most people with spinal muscular atrophy due to weak back muscles, potentially requiring surgical correction.
- Joint contractures can limit mobility and cause pain, while muscle weakness may lead to fractures from minor trauma.
- Nutritional challenges arise when swallowing muscles weaken, sometimes necessitating feeding tubes to prevent aspiration and ensure adequate nutrition.
- However, early treatment with new therapies has dramatically reduced the frequency and severity of these complications for many patients.
Prevention
- In vitro fertilization with preimplantation genetic testing
- Prenatal diagnosis through chorionic villus sampling or amniocentesis
- Donor gametes to avoid passing on the genetic mutation
Treatment for spinal muscular atrophy has undergone a revolution in recent years.
Treatment for spinal muscular atrophy has undergone a revolution in recent years. Three FDA-approved medications now target the underlying genetic cause: nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi). These therapies work by either increasing SMN protein production or replacing the faulty gene entirely.
Nusinersen requires injection into the spinal fluid every four months after initial loading doses.
Nusinersen requires injection into the spinal fluid every four months after initial loading doses. Zolgensma is a one-time gene therapy given intravenously, typically to infants under two years old. Risdiplam comes as a daily oral medication that can be taken at home, making it more convenient for long-term treatment.
Supportive care remains essential alongside these disease-modifying treatments.
Supportive care remains essential alongside these disease-modifying treatments. This includes: - Physical and occupational therapy to maintain mobility and function - Respiratory support ranging from airway clearance to mechanical ventilation - Nutritional support including feeding tubes when swallowing becomes difficult - Orthopedic interventions for scoliosis and joint contractures
The best outcomes occur when treatment starts early, ideally before significant symptoms develop.
The best outcomes occur when treatment starts early, ideally before significant symptoms develop. Many children receiving prompt treatment are now achieving motor milestones previously thought impossible, including sitting, standing, and even walking. Research continues into additional therapies, including muscle-directed treatments and combination approaches that may further improve outcomes.
Living With Spinal Muscular Atrophy
Living with spinal muscular atrophy requires a comprehensive approach that addresses both medical needs and quality of life. Many families find that assembling a multidisciplinary care team helps coordinate the various aspects of treatment. This typically includes neurologists, pulmonologists, orthopedic surgeons, nutritionists, and rehabilitation therapists working together.
Latest Medical Developments
Latest medical developments are being researched.
Frequently Asked Questions
Update History
Mar 8, 2026v1.0.0
- Published page overview and treatments by DiseaseDirectory